Angiotensin II-inhibiting drugs have no effect on intraneuronal aβ or oligomeric aβ levels in a triple transgenic mouse model of alzheimer's disease

American Journal of Translational Research

Volumn 3, Issue 2, 2011, Pages 197-208

  Ferrington, Linda ^a   Scott Miners, J ^b   Palmer, Laura E ^b   Bond, Susan M ^a   Povey, Joanne E ^a,c   Kelly, Paul A T ^a   Love, Seth ^b   Horsburgh, Karen J ^a   Kehoe, Patrick G ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Alzheimer's disease; Amyloid beta (A ); Angiotensin converting enzyme inhibitor; Angiotensin II receptor blocker; Triple transgenic mouse model

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; OLIGOMER; VALSARTAN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; ENZYME ACTIVITY; HEMISPHERE; IMMUNOHISTOCHEMISTRY; KIDNEY HOMOGENATE; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

EID: 79952977933     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Bayer TA and Wirths O. Intracellular accumulation of amyloid-Beta-a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. Front Aging Neurosci 2010; 2: 8.
2. Kehoe PG. The renin-angiotensin-aldosterone system and Alzheimer s disease? J Renin Angiotensin Aldosterone Syst 2003; 4: 80-93.
3. Poon IO. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy 2008; 28: 366-375.
4. Skoog I and Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 2006; 28: 605-611.
5. Wolozin B and Bednar MM. Interventions for heart disease and their effects on Alzheimer's disease. Neurol Res 2006; 28: 630-636.
6. Aalten P, Verhey FR, Boziki M, Brugnolo A, Bullock R, Byrne EJ, Camus V, Caputo M, Collins D, De Deyn PP, Elina K, Frisoni G, Holmes C, Hurt C, Marriott A, Mecocci P, Nobili F, Ousset PJ, Reynish E, Salmon E, Tsolaki M, Vellas B and Robert PH. Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord 2008; 25: 1-8.
7. Hajjar IM, Keown M, Lewis P and Almor A. Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: an observational study. Am J Alzheimers Dis Other Demen 2008; 23: 77-83.
8. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE and Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
9. Ohrui T, Matsui T, Yamaya M, Arai H, Ebihara S, Maruyama M and Sasaki H. Angiotensinconverting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 2004; 52: 649-650.
10. Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, Arai H and Sasaki H. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324-1325.
11. Rozzini L, Chilovi BV, Bertoletti E, Conti M, Del Rio I, Trabucchi M and Padovani A. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry 2006; 21: 550-555.
12. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B and Goff DC, Jr. Angiotensinconverting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the cardiovascular health study. Arch Intern Med 2009; 169: 1195-1202.
13. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS, Welsh-Bohmer KA and Breitner JC. Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study. Arch Neurol 2006;
14. Rosenberg PB, Mielke MM, Tschanz J, Cook L, Corcoran C, Hayden KM, Norton M, Rabins PV, Green RC, Welsh-Bohmer KA, Breitner JC, Munger R and Lyketsos CG. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry 2008; 16: 883-892.
15. Feigin VL. Stroke epidemiology in the developing world. Lancet 2005; 365: 2160-2161.
16. Pathak A, Hanon O, Negre-Pages L and Sevenier F. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients. Fundam Clin Pharmacol 2007; 21: 199-205.
17. Gard PR and Rusted JM. Angiotensin and Alzheimer's disease: therapeutic prospects. Expert Rev Neurother 2004; 4: 87-96.
18. Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nadhazi Z, Petrella R, Sedefdjian A, Sevenier F, Shlyakhto EV and Pathak A. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. J Hypertens 2008; 26: 1642-1650.
19. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A and Bulpitt C. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7: 683-689.
20. Kehoe PG. Angiotensins and Alzheimer's disease: a bench to bedside overview. Alzheimers Res Ther 2009; 1: 3.
21. Kehoe PG, Miners S and Love S. Angiotensins in Alzheimer's disease-friend or foe? Trends Neurosci 2009; 32: 619-628.
22. Kehoe PG and Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007; 6: 373-378.
23. Hemming ML and Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensinconverting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005; 280: 37644-37650.
24. Hou DR, Wang Y, Zhou L, Chen K, Tian Y, Song Z, Bao J and Yang QD. Altered angiotensinconverting enzyme and its effects on the brain in a rat model of Alzheimer disease. Chin Med J (Engl) 2008; 121: 2320-2323.
25. Hu J, Igarashi A, Kamata M and Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001; 276: 47863-47868.
26. Oba R, Igarashi A, Kamata M, Nagata K, Takano S and Nakagawa H. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci 2005; 21: 733-740.
27. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C and Pasinetti GM. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117: 3393-3402.
28. Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, Gong JS, Yu W, Yamamoto T, Kosaka K, Yanagisawa K and Michikawa M. Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci 2007; 27: 8628-8635.
29. Kehoe PG and Wilcock GK. The Renin Angiotensin System in Alzheimer's Disease-Updates Highlight a Clinical and Biological Dichotomy? Current Alzheimer Research 2006; 3: 171-173.
30. Mogi M, Li JM, Tsukuda K, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M and Horiuchi M. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun 2008; 375: 446-449.
31. Mogi M, Tsukuda K, Li JM, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M and Horiuchi M. Inhibition of cognitive decline in mice fed a highsalt and cholesterol diet by the angiotensin receptor blocker, olmesartan. Neuropharmacology 2007; 53: 899-905.
32. Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, Kano M, Ogihara T, Rakugi H and Morishita R. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009; 54: 1345-1352.
33. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y and LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-421.
34. Lorenz JN. A practical guide to evaluating cardiovascular, renal, and pulmonary function in mice. Am J Physiol Regul Integr Comp Physiol 2002; 282: R1565-R1582.
35. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S and Kehoe PG. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2008; 34: 181-193.
36. Sun X, Becker M, Pankow K, Krause E, Ringling M, Beyermann M, Maul B, Walther T and Siems W-E. Catabolic attacks of membrane-bound angiotensin-converting enzyme on the Nterminal part of species-specific amyloid-[beta] peptides. European Journal of Pharmacology 2008; 588: 18-25.
37. Toropygin IY, Kugaevskaya EV, Mirgorodskaya OA, Elisseeva YE, Kozmin YP, Popov IA, Nikolaev EN, Makarov AA and Kozin SA. The Ndomain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2008; 22: 231-239.
38. Hemming ML, Selkoe DJ and Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis 2007; 26: 273-281.
39. Yamada K, Uchida S, Takahashi S, Takayama M, Nagata Y, Suzuki N, Shirakura S and Kanda T. Effect of a centrally active angiotensinconverting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Res 2010; 1352: 176-186.
40. Miners S, Ashby E, Baig S, Harrison R, Tayler H, Speedy E, Prince JA, Love S and Kehoe PG. Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res 2009; 1: 163-177.
41. Alves MF, Araujo MC, Juliano MA, Oliveira EM, Krieger JE, Casarini DE, Juliano L and Carmona AK. A continuous fluorescent assay for the determination of plasma and tissue angiotensin Iconverting enzyme activity. Brazilian Journal of Medical and Biological Research 2005; 38: 8.
42. Oliveira EM, Santos RAS and Krieger JE. Standardization of a fluorimetric assay for the determination of tissue angiotensin-converting enzyme activity in rats. Brazilian Journal of Medical and Biological Research 2000; 33: 755-764.